Corcept Therapeutics Revenue, Profits - CORT Quarterly Income Statement

Add to My Stocks
$14.74 $0.35 (2.43%) CORT stock closing price Sep 17, 2018 (Closing)

CORT stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Corcept Therapeutics stock price. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has grown from 57.66M to 62.31M and how operating and non operating activities have impacted the CORT stock. One also needs to look at Corcept Therapeutics assets, operating expenses and Corcept Therapeutics free cash flow. The Corcept Therapeutics profit and loss statement shows revenue of $62.31M for 2018 Q2. Revenue has grown by 8.06% QoQ for CORT stock.

View and download details of revenue and profits for Corcept Therapeutics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Corcept Therapeutics Revenues or Net Sales
62.31M57.66M53.28M42.76M35.56M27.6M23.81M21.73M19.72M16.06M
Cost Of Goods Sold (COGS)1.15M1.17M1.17M-------
Corcept Therapeutics Gross Profit
61.16M56.48M52.13M41.78M34.78M26.95M23.27M21.05M19.29M15.65M
Research & Development Expense20.54M17.05M13.64M11.69M7.87M7.17M6.49M7.05M5.67M4.63M
Selling General & Admin Expense19.98M18.44M16.8M16.47M14.11M15.03M11.77M10.93M12.11M10.43M
Income Before Depreciation Depletion Amortization20.63M20.99M21.7M13.62M12.79M4.74M5.01M3.07M1.5M-
Depreciation Depletion Amortization----------
Non Operating Income---0.08M-------
Interest Expense---0.27M-------
Corcept Therapeutics Pretax Income
21.2M21.28M21.9M13.7M12.69M4.51M4.6M2.58M--0.01M
Provision for Income Taxes3M3.83M-76.44M-0.04M------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations18.2M17.31M98.33M13.76M12.65M4.39M4.6M2.59M--0.02M
Extraordinary Items & Discontinued Operations----------
Corcept Therapeutics Profit/ Loss (Net Income)
18.2M17.31M98.33M13.76M12.65M4.39M4.6M2.59M--0.02M
Average Shares used to compute Diluted EPS127.52M127.73M127.36M125.65M123.01M121.19M118.87M116.42M115.33M109.66M
Average Shares used to compute Basic EPS115.49M114.88M114.37M113.6M113.25M112.87M111.9M110.65M110.03M109.66M
Income Before Nonrecurring Items18.2M17.31M21.63M13.76M12.65M4.39M4.6M2.59M--0.02M
Income from Nonrecurring Items--76.7M-------
Corcept Therapeutics Earnings Per Share Basic Net
0.160.150.860.120.110.040.040.020.010.00
Corcept Therapeutics Earnings Per Share Diluted Net
0.140.140.770.110.100.040.040.020.010.00
EPS Diluted Before Nonrecurring Items0.140.140.170.110.100.040.040.020.010.00
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Corcept Therapeutics stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Corcept Therapeutics revenue chart, implies that the company is growing. It has been the case with Corcept Therapeutics. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. CORT stock had a healthy bottom line growth.

The income statement is also called the profit and loss statement. Apart from the CORT income statement, one can check the Corcept Therapeutics historical stock prices to check how the price has moved with time.

Corcept Therapeutics Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
12.71
PS Ratio (price sales ratio)
7.88
Operating Margin
33.1
Net Profit Margin
29.2
Dividend Yield
0%